Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-08-12 16:14:48 ET · period of report 2026-08-10 · accession 0001681643-26-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-12 16:14 | 2026-08-10 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $376.69 | +800 | 2,503 | +47% | +$301.4K |
| DT | 2026-08-12 16:14 | 2026-08-10 | REGN | Zoghbi Huda Y | Dir | S - Sale+OE | $800.00 | -800 | 1,703 | -32% | -$640.0K |
| DT | 2026-08-12 16:14 | 2026-08-10 | REGN | Zoghbi Huda Y | Dir | M - OptEx | $0.00 | -800 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-10 | M | A | 800 | $376.69 | 2,503 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. |
| 2 | Common | Common Stock | 2026-08-10 | S | D | 800 | $800.00 | 1,703 | D | — | — | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-08-10 | M | D | 800 | $0.00 | 0 | D | $376.69 · — to 2027-01-03 | 800 Common Stock | (F1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on November 20, 2025. (F2) The stock option vested in three equal annual installments, commencing one year after the date of grant. |